Takeda Pharmaceutical Company Limited
TAK
$17.63
$0.241.38%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -1.07% | -0.95% | -1.29% | -2.14% | 1.39% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.07% | -0.95% | -1.29% | -2.14% | 1.39% |
| Cost of Revenue | 0.30% | 3.52% | -1.77% | 1.04% | 4.56% |
| Gross Profit | -1.81% | -3.28% | -1.04% | -3.78% | -0.24% |
| SG&A Expenses | -1.92% | -1.37% | 0.47% | -0.89% | 1.04% |
| Depreciation & Amortization | -14.64% | -7.73% | -1.08% | 79.11% | -0.89% |
| Other Operating Expenses | 106.91% | -23.78% | -38.95% | 462.04% | -35.42% |
| Total Operating Expenses | -2.51% | -1.90% | -1.26% | 9.11% | 0.58% |
| Operating Income | 9.28% | 5.85% | -1.52% | -47.40% | 7.62% |
| Income Before Tax | -159.56% | -164.92% | -8.75% | -60.38% | 328.54% |
| Income Tax Expenses | -35.38% | -75.70% | 275.59% | 389.12% | 153.11% |
| Earnings from Continuing Operations | -205.50% | -219.86% | -43.13% | -86.47% | -1.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -39.06% | -22.81% | -43.34% | -24.35% | -17.00% |
| Net Income | -205.84% | -220.35% | -43.21% | -86.54% | -1.63% |
| EBIT | 9.28% | 5.85% | -1.52% | -47.40% | 7.62% |
| EBITDA | -1.76% | 0.12% | -1.34% | -28.16% | 2.86% |
| EPS Basic | -204.97% | -218.53% | -42.60% | -86.16% | -1.48% |
| Normalized Basic EPS | 13.30% | 7.46% | 10.57% | -55.99% | 9.27% |
| EPS Diluted | -209.87% | -225.06% | -43.64% | -86.70% | -3.07% |
| Normalized Diluted EPS | 13.80% | 7.88% | 11.01% | -55.96% | 8.40% |
| Average Basic Shares Outstanding | 0.03% | -0.28% | -0.04% | 0.32% | 0.69% |
| Average Diluted Shares Outstanding | 0.05% | -0.22% | 0.01% | -0.06% | 1.17% |
| Dividend Per Share | 0.13% | 0.13% | 2.22% | 2.22% | 1.44% |
| Payout Ratio | -1.91% | -1.88% | 0.88% | 6.95% | 0.09% |